This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, and takes a look at two favorite health-care-focused dividend stocks. Market Checkup gives a full examination of the recent regulatory action around a new blood cancer drug, a European orphan drug approval, and why a big pharma shockingly stopped the FDA from reviewing its newest diabetes drug.

In this video, health-care analysts David Williamson and Max Macaluso discuss Gilead's (NASDAQ:GILD)  new drug application for idelalisib, which treats Non-Hodgkin's Lymphoma. Watch and find out how it stacks up against its competition, its sales potential, and its overall importance to the big biotech.

Follow David on Twitter: @MotleyDavid.

David Williamson owns shares of Johnson & Johnson. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.